Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 33Leukemia, Myeloid, Acute 31Leukemia, Lymphocytic, Chronic, B-Cell 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 18Lymphoma, Non-Hodgkin 18Lymphoma 17Hodgkin Disease 16Multiple Myeloma 12Lymphoma, Mantle-Cell 11Recurrence 10Melanoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Burkitt Lymphoma 10Waldenstrom Macroglobulinemia 8Neoplasms, Plasma Cell 8Neoplasm Metastasis 8Myeloproliferative Disorders 8Leukemia, Myeloid, Accelerated Phase 8Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Biphenotypic, Acute 7Hematologic Neoplasms 7Congenital Abnormalities 7Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6

Interventions

otelixizumab 1fludarabine phosphate 1fludarabine 1Metoprolol 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1Etanercept 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cytokine Release Syndrome × fludarabine phosphate × Clear all
NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡